The clinical trial report, “Hepatitis B - Global Clinical Trials Review, 2026" provides an overview of Hepatitis B Clinical trials scenario. This report provides top line data relating to the clinical trials on Hepatitis B. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). The analyst Clinical Trial Reports are generated using the analyst’s proprietary database - Pharma - Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Report Scope
- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months
Reasons to Buy
- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level
Table of Contents
- Report Guidance
- The analyst Clinical Trials Report Coverage
- Clinical Trials by Region
- Clinical Trials and Average Enrollment by Country
- Top Five Countries Contributing to Clinical Trials in Asia-Pacific
- Top Five Countries Contributing to Clinical Trials in Europe
- Top Countries Contributing to Clinical Trials in North America
- Top Five Countries Contributing to Clinical Trials in Middle East and Africa
- Top Five Countries Contributing to Clinical Trials in Central and South America
- Clinical Trials by G7 Countries: Proportion of Hepatitis B to Infectious Disease Clinical Trials
- Clinical Trials by Phase in G7 Countries
- Clinical Trials in G7 Countries by Trial Status
- Clinical Trials by E7 Countries: Proportion of Hepatitis B to Infectious Disease Clinical Trials
- Clinical Trials by Phase in E7 Countries
- Clinical Trials in E7 Countries by Trial Status
- Clinical Trials by Phase
- In Progress Trials by Phase
- Clinical Trials by Trial Status
- Clinical Trials by End Point Status
- Subjects Recruited Over a Period of Time
- Clinical Trials by Sponsor Type
- Prominent Sponsors
- Top Companies Participating in Hepatitis B Therapeutics Clinical Trials
- Prominent Drugs
- Latest Clinical Trials News on Hepatitis B
- Feb 23, 2026: Aligos Therapeutics Presents Positive Data On Pevifoscorvir Sodium at the Conference on Retroviruses and Opportunistic Infections (CROI)
- Feb 22, 2026: Virion Reports Broad and Sustained Anti-HBV Immunity Following a Single VRON-0200 Dose From its Phase 1b Study at CROI 2026
- Feb 02, 2026: Hansoh Pharmaceutical Hengmu: A 5-Year Evidence-Based Collection Recommended by 14 Guidelines and Consensus Reports
- Jan 27, 2026: Voluntary Announcement Positive Results From Phase II Trial of TQA3605 “Core Protein Allosteric Modulator” for Chronic Hepatitis B
- Jan 21, 2026: Aligos Therapeutics Provides Phase 2 B-Supreme Study Progress Updates
- Jan 08, 2026: GSK to file for approval of twice-yearly hep B drug on positive Phase III data
- Jan 05, 2026: Voluntary Announcement Announcement on Phase I Clinical Trial of HECN30227 and Progress in the Development of Small Nucleic Acid Platform
- Dec 31, 2025: Chengdu Xinzhenghe Pharma’s LC-1016 Injection Receives the Clinical Trial Acceptance From NMPA
- Dec 23, 2025: AusperBio concludes enrolment in Phase III AUSHINE trial
- Dec 12, 2025: AusperBio Announces AHB-137 Monotherapy Achieved 30% Functional Cure Rate in HBe-negative CHB Patients on Stable Nucleos(t)ide Analogue (NA) Therapy
- Dec 11, 2025: Aligos Therapeutics Presents Positive Data at HEP-DART 2025
- Dec 11, 2025: Karolinska Development’s Portfolio Company SVF Vaccines Presents New Preclinical Data Demonstrating Extended Effect of SVF-001 in Hepatitis B and D
- Dec 07, 2025: Replicor Publishes Data From its Compassionate Access Program in HBV/HDV
- Clinical Trial Profile Snapshots
- Appendix
- Abbreviations
- Definitions
- Research Methodology
- Secondary Research
- About the Analyst
- Contact the Publisher
- Source
- Hepatitis B Therapeutics, Global, Clinical Trials by Region, 2026*
- Hepatitis B Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2026*
- Hepatitis B Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2026*
- Hepatitis B Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2026*
- Hepatitis B Therapeutics Clinical Trials, Europe, Top Five Countries, 2026*
- Hepatitis B Therapeutics Clinical Trials, North America, Top Countries, 2026*
- Hepatitis B Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2026*
- Hepatitis B Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2026*
- Proportion of Hepatitis B to Infectious Disease Clinical Trials, G7 Countries (%), 2026*
- Hepatitis B Therapeutics, G7 Countries, Clinical Trials by Phase, 2026*
- Hepatitis B Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2026*
- Proportion of Hepatitis B to Infectious Disease Clinical Trials, E7 Countries (%), 2026*
- Hepatitis B Therapeutics, E7 Countries, Clinical Trials by Phase, 2026*
- Hepatitis B Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2026*
- Hepatitis B Therapeutics, Global, Clinical Trials by Phase, 2026*
- Hepatitis B Therapeutics, Global, Clinical Trials In Progress by Phase 2026*
- Hepatitis B Therapeutics, Global, Clinical Trials by Trial Status, 2026*
- Hepatitis B Therapeutics Clinical Trials, Global, by End Point Status, 2026*
- Hepatitis B Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2021-2025
- Hepatitis B Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2026*
- Hepatitis B Therapeutics Clinical Trials, Global, Key Sponsors, 2026*
- Hepatitis B Therapeutics Clinical Trials, Global, Top Companies by Phase, 2026*
- Hepatitis B Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2026*
- Hepatitis B Therapeutics, Global, Clinical Trials by Region (%), 2026*
- Hepatitis B Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2026*
- Hepatitis B Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2026*
- Hepatitis B Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2026*
- Hepatitis B Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2026*
- Hepatitis B Therapeutics Clinical Trials, North America, Top Countries (%), 2026*
- Hepatitis B Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2026*
- Hepatitis B Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2026*
- Proportion of Hepatitis B to Infectious Disease Clinical Trials, G7 Countries (%), 2026*
- Hepatitis B Therapeutics, G7 Countries, Clinical Trials by Phase, 2026*
- Hepatitis B Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2026*
- Proportion of Hepatitis B to Infectious Disease Clinical Trials, E7 Countries (%), 2026*
- Hepatitis B Therapeutics, E7 Countries, Clinical Trials by Phase, 2026*
- Hepatitis B Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2026*
- Hepatitis B Therapeutics, Global, Clinical Trials by Phase (%), 2026*
- Hepatitis B Therapeutics, Global, Clinical Trials In Progress by Phase, 2026*
- Hepatitis B Therapeutics, Global, Clinical Trials by Trial Status, 2026*
- Hepatitis B Therapeutics Clinical Trials, Global, by End Point Status, 2026*
- Hepatitis B Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2021-2025
- Hepatitis B Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2026*
- Hepatitis B Therapeutics Clinical Trials, Global, Key Sponsors, 2026*
- Hepatitis B Therapeutics Clinical Trials, Global, Top Companies by Phase, 2026*
- Hepatitis B Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2026*
- The analyst Methodology
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- GSK plc
- Gilead Sciences Inc
- Roche Holding AG
- Sanofi
- Bristol-Myers Squibb Co
- Merck & Co Inc
- Novartis AG
- Novotech Health Holdings Pte Ltd
- Johnson & Johnson
- Arbutus Biopharma Corp
